aducanumab

Let’s get right to it.

Recently the U.S. Food and Drug Administration granted accelerated approval to aducanumab (Aduhelm), the first Alzheimer’s Disease treatment since 2003.

The FDA perspective If you need to get up to speed on the controversy, look here. The approval was based on three studies.

What we know – providing context